/SELB

SELB Stock - Selecta Biosciences, Inc.

Q: What is the analyst price target for SELB?

Analyst price target information is not currently available for SELB.

Q: What is SELB's market cap?

Market capitalization information is not currently available for SELB.

Healthcare|Biotechnology|NASDAQ

$0.88-8.00%

$0.08 (-8.00%) • Nov 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.97

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SELB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.83

52W High$1.99

52W Low$0.79

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$38.91M	N/A	$110.78M	$85.08M	$16.60M
Gross Profit	N/A	N/A	$38.40M	$16.34M	$-37,908,000
Gross Margin	0.0%	N/A	34.7%	19.2%	-228.4%
Operating Income	N/A	$-86,416,000	$14.54M	$-4,597,000	$-56,821,000
Net Income	$-77,424,000	$-219,710,000	$35.38M	$-25,687,000	$-69,787,000
Net Margin	-199.0%	N/A	31.9%	-30.2%	-420.5%
EPS	$-0.50	$-1.42	$0.24	$-0.22	$-0.69

Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 391.8% Upside

Now

Low

Average

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 18th 2023	SVB Securities	Downgrade	Market Perform	$1
June 14th 2022	Needham	Reiterated	Buy	$5← $6
June 6th 2022	SVB Leerink	Initiation	Outperform	$7

Earnings History & Surprises

SELB

Beat Rate

59%

Last 17 quarters

Avg Surprise

-54.0%

EPS vs Estimate

Beats / Misses

10/7

Last 12 quarters

Latest EPS

$-0.01

Q4 2023

EPS Surprise History

Q1 22

+42.9%

$-0.04vs$-0.07

Q2 22

+22.2%

$-0.07vs$-0.09

Q3 22

+175.0%

$0.06vs$-0.08

Q4 22

-777.2%

$-0.01vs$-0.00

Q1 23

-154.9%

$-0.03vs$-0.01

Q2 23

-37.5%

$-0.11vs$-0.08

Q3 23

+22.2%

$-0.07vs$-0.09

Q4 23

+85.7%

$-0.01vs$-0.07

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 15, 2024	—	—	—	—
Q2 2024	May 2, 2024	—	—	—	—
Q1 2024	Mar 7, 2024	$-0.05	—	—	—
Q4 2023	Nov 2, 2023	$-0.07	$-0.01	+85.7%	✓ BEAT
Q3 2023	Aug 17, 2023	$-0.09	$-0.07	+22.2%	✓ BEAT
Q2 2023	May 4, 2023	$-0.08	$-0.11	-37.5%	✗ MISS
Q1 2023	Mar 2, 2023	$-0.01	$-0.03	-154.9%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.00	$-0.01	-777.2%	✗ MISS
Q3 2022	Aug 4, 2022	$-0.08	$0.06	+175.0%	✓ BEAT
Q2 2022	May 5, 2022	$-0.09	$-0.07	+22.2%	✓ BEAT
Q1 2022	Mar 10, 2022	$-0.07	$-0.04	+42.9%	✓ BEAT
Q4 2021	Nov 9, 2021	$-0.07	$-0.16	-128.6%	✗ MISS
Q3 2021	Aug 12, 2021	$-0.09	$-0.04	+55.6%	✓ BEAT
Q2 2021	May 13, 2021	$-0.12	$-0.22	-83.3%	✗ MISS
Q1 2021	Mar 11, 2021	$-0.15	$-0.14	+6.7%	✓ BEAT
Q4 2020	Nov 5, 2020	$-0.12	$-0.09	+25.0%	✓ BEAT
Q3 2020	Aug 6, 2020	$0.32	$-0.17	-153.1%	✗ MISS
Q2 2020	May 7, 2020	$-0.27	$-0.21	+22.2%	✓ BEAT
Q1 2020	Mar 12, 2020	$-0.19	$-0.28	-47.4%	✗ MISS
Q4 2019	Nov 8, 2019	$-0.28	$-0.26	+7.1%	✓ BEAT

Frequently Asked Questions about SELB

What is SELB's current stock price?

Selecta Biosciences, Inc. (SELB) is currently trading at $0.88 per share. The stock has moved -8.00% today.

What is the analyst price target for SELB?

No analyst price targets are currently available for this stock.

What sector is Selecta Biosciences, Inc. in?

Selecta Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is SELB's market cap?

Selecta Biosciences, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.

Does SELB pay dividends?

No, Selecta Biosciences, Inc. does not currently pay a dividend to shareholders.